New!

Massachusetts Department of Public Health
Recommendations and Resources for the Control of Influenza and Pneumococcal Disease:
2016 – 2017 Updated 12-13-2016

Update December 2016 - FluLaval: On 11-18-16, the FDA lowered the minimum age for use of FluLaval from 3 years old to 6 months. FluLaval is approved as a 0.5 mL dose, including in this younger age group. This is different from Fluzone, which is approved as a 0.25 mL dose in those 6-35 months. Providers should be vigilant to ensure that patients 6–35 months receive the correct dose, depending on formulation used. See pages 11 and 12. Updated language is highlighted in yellow.

Everyone aged 6 months and older should receive flu vaccine every year. This season, the Advisory Committee on Immunization Practices (ACIP) is recommending vaccination with either the inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV). Vaccination should not be delayed to procure a specific vaccine formulation. Begin offering flu vaccine as soon as it is available.

This year there is no preferential recommendation for any one age-appropriate inactivated flu formulation over another. Choice of which influenza vaccine formulation to use should primarily be driven by the age indication, contraindications and precautions. There is no current preference for quadrivalent vs. trivalent or high-dose vs. adjuvanted vs standard dose.

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunization Rates</td>
<td>2</td>
<td>Influenza Reporting</td>
<td>6</td>
</tr>
<tr>
<td>Influenza Vaccine Recommendations</td>
<td>2</td>
<td>Influenza Testing</td>
<td>6</td>
</tr>
<tr>
<td>o Timing</td>
<td>3</td>
<td>Specimen Collection and Shipping</td>
<td>7</td>
</tr>
<tr>
<td>o LAIV New!</td>
<td>3</td>
<td>Infection Control</td>
<td>7</td>
</tr>
<tr>
<td>o Egg Allergies New!</td>
<td>3</td>
<td>Novel Strains</td>
<td>8</td>
</tr>
<tr>
<td>o Doses Recommended &lt; 9 Years</td>
<td>5</td>
<td>Antiviral Treatment</td>
<td>8</td>
</tr>
<tr>
<td>o Travelers</td>
<td>5</td>
<td>Vaccine Ordering and Locating Clinics</td>
<td>8</td>
</tr>
<tr>
<td>o Neurologic Conditions and Congregate Housing</td>
<td>5</td>
<td>Guidance Large Scale Clinics New!</td>
<td>9</td>
</tr>
<tr>
<td>Influenza Surveillance</td>
<td>6</td>
<td>Table 1: Approved Vaccine Formulations</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>References and Resources</td>
<td>12</td>
</tr>
</tbody>
</table>

What's New for the 2016-2017 Flu Season?

2016-2017 influenza vaccine composition: For 2016–17, U.S.-licensed influenza vaccines are different from the 2015–16 vaccines. The composition for 2016-17 represents a change in the influenza A(H3N2) virus, and a switch in lineage for the influenza B viruses.

- Trivalent influenza vaccines contain:
  - an A/California/7/2009 (H1N1)pdm09-like virus
  - an A/Hong Kong/4801/2014 (H3N2)-like virus (New!)
  - a B/Brisbane/60/2008-like (Victoria lineage) virus (this strain was in last year’s quadrivalent vaccine)

- Quadrivalent vaccines contain the above three viruses and a second influenza B strain, B/Phuket/3073/2013-like/(Yamagata lineage) virus (this strain was in last year’s trivalent and quadrivalent vaccines)

Live attenuated influenza vaccine (LAIV) is not recommended for the 2016-2017 season:
The ACIP has made an interim recommendation that quadrivalent live attenuated influenza vaccine (LAIV4) should not be used for the 2016-2017 flu season. Please see page 3 in this advisory for additional details.

Changes to Guidelines Related to Egg Allergy:
The ACIP now recommends that any licensed influenza vaccine formulation may be administered to persons with egg allergy of any severity. Please see page 3 in this advisory for more detailed guidance to ensure proper evaluation and safe administration.

New Formulations:

- Fluad (Seqirus) contains the adjuvant MF59 and is an inactivated trivalent vaccine for persons ≥65 years of age. Adjuvants help create a stronger immune response to vaccines.
- Flucelvax Quadrivalent (Seqirus) is a cell culture-based inactivated quadrivalent influenza vaccine for persons ≥4 years of age. (Last year this vaccine had been trivalent and only approved for those ≥18 years.)
- Afluria quadrivalent inactivated influenza vaccine (Sequiris) was licensed by the FDA in August 2016, for use in persons 18 years of age and older.
Vaccine Supply:
Early projections of influenza vaccine supply for the upcoming season were between 157-188 million doses, of which LAIV represented about 14 million or 8%. Based on these projections, we expect the supply of IIV for the coming season to be adequate.

- MDPH has worked with CDC and the manufacturers to order adequate amounts of state-supplied IIV. Please consult the MDPH LAIV resource page.
- Providers who privately purchase flu vaccine can consult the Influenza Vaccine Availability Tracking System to order additional doses and see the report of manufacturers and distributors that have influenza vaccine. There is also an updated list of flu vaccine products available for the U.S. for the 2016-17 season.
- Most manufacturers began shipping vaccine in August.

VIS Information: Influenza VISs are no longer updated each year, unless needed. The current flu VIS posted on the CDC website is the one you can use for this upcoming flu season. If you need VIS in other languages, please visit http://www.immunize.org/vis/vis_flu_inactive.asp

Influenza Vaccination Rates in Massachusetts:
During the 2014-2015 flu season, 55% of Massachusetts residents received flu vaccine. The highest rate (81%) in Massachusetts was among children 6 months - 4 years of age, where MA ranked 4th in the nation. Massachusetts ranked first in the nation for vaccination of 13-17 year olds, which was the only group with a statistically significant change from 2013-14. The lowest rate (45%) was among adults 18-64 years of age.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Everyone 6 mos +</td>
<td>53%</td>
<td>55%</td>
<td>+2</td>
</tr>
<tr>
<td>Children 6 mos – 17 yrs</td>
<td>72%</td>
<td>76%</td>
<td>+4</td>
</tr>
<tr>
<td>- Children 6 mos – 4 yrs</td>
<td>87%</td>
<td>81%</td>
<td>-6</td>
</tr>
<tr>
<td>- Children 5 – 12 yrs</td>
<td>72%</td>
<td>78%</td>
<td>+6</td>
</tr>
<tr>
<td>- Adolescents 13 – 17 yrs</td>
<td>61%</td>
<td>71%</td>
<td>+10</td>
</tr>
<tr>
<td>Adults 18 yrs +</td>
<td>49%</td>
<td>50%</td>
<td>+1</td>
</tr>
<tr>
<td>- Adults 18 – 64 yrs</td>
<td>45%</td>
<td>45%</td>
<td>0</td>
</tr>
<tr>
<td>- Adults, 18-64 yrs, High Risk</td>
<td>58%</td>
<td>53%</td>
<td>-5</td>
</tr>
<tr>
<td>- Adults 65 yrs +</td>
<td>64%</td>
<td>67%</td>
<td>+3</td>
</tr>
</tbody>
</table>

Source: NIS-Flu

Your recommendation and offer of vaccine are the most important determinants of whether or not your patient gets vaccinated: In 2013 (the most recent year where data are available), 71% of pregnant women in Massachusetts received a flu shot, compared with 66% in 2012 (MA Pregnancy Risk Assessment Monitoring System [PRAMS]). A recent CDC national survey of pregnant women found that 68% of pregnant women in the US whose provider recommended and offered them flu vaccine received the vaccine, compared with only 9% of pregnant women whose provider did not recommend vaccine, and 34% whose provider recommended vaccine but did not offer it. These data underscore the importance of providers not only strongly recommending vaccination, but also offering vaccine on site.

Influenza Vaccine Recommendations
The ACIP’s 2016-2017 Influenza Vaccine Recommendations are summarized below.

Influenza Vaccine Formulations Available for the 2016-2017 Season:
Please see Table 1 on page 11 of this advisory for the Approved Inactivated Influenza Vaccine Formulations for 2016-2017. Because LAIV is not being recommended by the ACIP this season, providers may be receiving influenza vaccine formulations they are not familiar with. Please take time to ensure you are using the age-appropriate formulation and dose for the person you are vaccinating. We hope Table 1 will assist you in this effort to reduce medical errors.

Timing of Flu Vaccination:
Vaccination should occur before the onset of influenza activity in the community. To avoid missed opportunities for vaccination, providers should offer flu vaccination at routine health visits and hospitalizations as soon as vaccine is available, particularly for young children who may need two doses. Although CDC recommends vaccination occur by October if possible, vaccination should continue to be offered in November and throughout the flu season as long as flu viruses are circulating. While seasonal influenza outbreaks can happen as early as October, most of the time influenza activity peaks in January or later. Since it takes about two weeks after vaccination for antibodies to develop in the body that protect against influenza virus infection, it is best that people get vaccinated so they are protected before influenza begins spreading in their community. In New England, flu activity lasts usually through April and May.

Use annual flu vaccination to assess patients for the need for other vaccines, including Tdap and pneumococcal conjugate (PCV13) and pneumococcal polysaccharide (PPSV23) vaccines.

### New!

#### Live Attenuated Influenza Vaccine Not Recommended for the 2016-2017 Season

The Advisory Committee on Immunization Practices (ACIP) has made an interim recommendation that LAIV4 should not be used for the 2016-2017 flu season. This recommendation was made in light of the poor vaccine effectiveness against influenza A (H1N1) in the U.S. during the 2013-2014 and 2015-2016 seasons.

Possible causes for reduced LAIV effectiveness include: 1) suboptimal performance of the new A/Bolivia(H1N1) vaccine component which had been added this past year to make vaccine more heat stable; 2) potential interference among live viruses in the quadrivalent vaccine; and 3) reduced immunogenicity of LAIV as a result of a more highly vaccinated population in recent years, compared to populations of earlier years. There are no concerns about the safety of LAIV.

How well the flu vaccine works (or its ability to prevent flu illness) can range widely from season to season and can be affected by a number of factors, including characteristics of the person being vaccinated, the similarity between vaccine viruses and circulating viruses, and the vaccine formulations used.

The change in the LAIV recommendation for this flu season is the result of the annual efforts to measure influenza vaccine effectiveness. It is an example of CDC and the ACIP using new data to hone public health policy in order to recommend the most effective vaccines. Researchers, CDC, the FDA and AstraZeneca (manufacturer of FluMist), are all committed to gaining insight into this issue and are continuing to review data as it becomes available. Although not recommended by the ACIP for the 2016-17 season, because LAIV is a licensed product, it is available for purchase.

For more information, see CDC’s press release explaining the decision, and pages 14-17 in the ACIP recommendations. In addition, CDC’s flu website is being updated to reflect these all these recommendations. We have also created an MDPH LAIV resource page.

### Changes to guidance related to the management of egg allergic persons:

Anaphylaxis after influenza vaccine is rare, about 1.3 to 1.5 events per million doses, about the same rate as anaphylaxis after other childhood vaccines. As is the case with other vaccines, influenza vaccines contain various different components that may cause allergic reactions. Reviews of studies of experience with the use of IIV, and more recently LAIV, indicate that severe allergic reactions to the currently available egg-based influenza vaccines in persons with egg allergy of any severity are unlikely.

#### Recommendation

Although history of severe allergic reaction is a labeled contraindication to influenza vaccines, this year the ACIP recommends that any licensed influenza vaccine formulation may be administered to persons with egg allergy of any severity. To ensure safety, providers should follow the guidance outlined below:

a. Persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Any licensed and recommended influenza vaccine (i.e., any age-appropriate IIV or RIV) that is otherwise appropriate for the recipient’s age and health status may be used.

b. Persons who report having had reactions to egg involving symptoms other than hives, such as angioedema, respiratory distress, lightheadedness, or recurrent emesis; or who required epinephrine or another emergency medical intervention, may similarly receive any licensed and recommended influenza vaccine (i.e., any age-appropriate IIV or RIV) that is otherwise appropriate for the recipient’s age and health status. The selected vaccine should be administered in an inpatient or outpatient medical setting (including but not necessarily limited to hospitals, clinics, and physician offices).

Vaccine administration should be supervised by a healthcare provider who is able to recognize
and manage severe allergic conditions. Clinics and practices will need to determine if they have the trained staff, protocols and equipment in place to safely vaccinate those with severe egg allergy or refer them to their medical home or another provider.

c. A previous severe allergic reaction to influenza vaccine, regardless of vaccine component suspected of being responsible, is a contraindication to future receipt of the vaccine.

d. The ACIP does not express a preference for the use of egg-free flu formulations in egg-allergic patients. However, an egg-free recombinant flu vaccine (RIV3), Flublok, is available for those ≥18 years of age and some providers may choose to administer RIV3 to their severely egg-allergic patients. The cell culture vaccine, Flucelvax, has a much smaller amount of egg protein since the original virus was grown in eggs, but mass production of that vaccine does not occur in eggs. Flucelvax contains an estimated total egg protein that is less than 50 femtograms (5x10^-8 µg) total egg protein (and less ovalbumin) per 0.5 mL dose.

Remember, persons who are able to eat lightly cooked egg (e.g., scrambled egg) without reaction are unlikely to be allergic and can receive any licensed influenza vaccine. Egg-allergic persons might tolerate egg in baked products (e.g., bread or cake). Tolerance to egg-containing foods does not exclude the possibility of egg allergy. Egg allergy can be confirmed with a consistent medical history of adverse reactions to eggs and egg-containing foods, plus skin and/or blood testing for immunoglobulin E antibodies to egg proteins.

Observation period after vaccination
In addition, egg allergic individuals no longer need to be observed for 30 minutes post vaccination for signs and symptoms of allergic reactions. According to the Vaccine Safety Datalink (VSD) study of over 25 million doses, anaphylaxis occurred at rate of 1.31 per million. In over 60% of the cases, they occurred at greater than 30 minutes post vaccination. However, providers should continue with the general recommendation to observe all patients for 15 minutes after vaccination to decrease the risk for injury should they experience syncope.

For full guidance on management of those with egg allergy, see pages 26, 29-30 and 33 in the ACIP recommendations.

General Plan for Response to Acute Vaccine Reactions
Although anaphylactic reactions are rare after vaccination, their immediate onset and life-threatening nature require that all personnel and facilities providing vaccinations have procedures in place for anaphylaxis management. All vaccination providers should be familiar with the office emergency plan and be currently certified in cardiopulmonary resuscitation. Epinephrine and equipment for maintaining an airway should be available for immediate use.
Vaccine Dose Considerations for Children 6 Months through 8 Years of Age:
The algorithm for determining the appropriate number of doses for children aged 6 months through 8 years has not changed for 2016-2017.

- Children 6 months through 8 years who have previously received 2 or more total doses of trivalent or quadrivalent influenza vaccine as of July 1, 2016 need only 1 dose for the 2016-17 season. The two previous doses do not need to have been given during the same season or consecutive seasons.

- Children 6 months through 8 years who have previously received only 1 dose or no doses of influenza vaccine need two doses of vaccine to be fully protected for the 2016-2017 season.

Figure 1: Flu vaccine dosing algorithm for children 6 months through 8 years of age, 2016-2017

Information for Travelers:
The Southern Hemisphere experiences its flu season from April through September, and flu activity can occur year-round in the tropics. People traveling to parts of the world where flu activity is ongoing, and who have not received flu vaccine for the current season, should get vaccinated. This is particularly important for people at risk for flu-related complications. This also applies to people who are traveling in the temperate regions of the Northern Hemisphere as part of tourist groups (e.g., on cruise ships) that may include people from other parts of the world where flu activity is ongoing. For more information, go to: www.cdc.gov/flu/travelers/travelersfacts.htm.

Influenza, Neurologic and Neuromuscular Conditions, and Congregate Housing:
Children and adults with neurological and neuromuscular conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy [seizure disorders], stroke, intellectual disability [mental retardation], moderate to severe developmental delay, muscular dystrophy, or spinal cord injury) are at increased risk of complications from influenza. These conditions can compromise respiratory function, handling of secretions and increase the risk of aspiration. Like everyone else six months of age and older, they should receive influenza vaccine every year. A CDC study found that in 2011-2012, only about half of children and young adults within this high risk group received influenza vaccine.

People with neurological and neuromuscular conditions who live in congregate housing (e.g., group homes) and/or attend day programs may be exposed to influenza throughout the season. They should receive flu vaccine as soon as it is available. Staff at these facilities should be vaccinated as well. In addition, when outbreaks of influenza-like illness (fever with cough and/or sore throat) occur in a group home or day program serving vulnerable populations, healthcare providers should be immediately notified and should consider rapid antiviral treatment of ill individuals as well as antiviral prophylaxis of individuals who were exposed.

Outbreaks across the age spectrum in these settings have occurred annually in Massachusetts and have resulted in serious illness and even death. So, MDPH recommends:

- Annual vaccination of residents and staff, and rapid outbreak response can prevent serious illness and death.
Proactive development of an influenza outbreak response protocol within agencies serving vulnerable populations, to facilitate a rapid response when an outbreak occurs. For more information see [http://www.cdc.gov/ncbddd/developmentaldisabilities/features/keyfinding-flu-vaccine-neurologic.html](http://www.cdc.gov/ncbddd/developmentaldisabilities/features/keyfinding-flu-vaccine-neurologic.html)

Immediate notification of MDPH and other appropriate agencies (see below).

**Influenza Surveillance:**
Throughout the year, and especially during flu season, conduct surveillance for respiratory illness with fever and use influenza testing to identify outbreaks so infection control measures can be promptly initiated in all settings, including inpatient and outpatient settings.

**Influenza Reporting:**
All positive laboratory findings indicative of influenza virus infection are reportable directly to MDPH, in accordance with 105 CMR 300.000 (Reportable Diseases, Surveillance and Isolation and Quarantine Requirements).

1) **Immediately report the following influenza-related cases by phone to the Division of Epidemiology and Immunization at 617-983-6800 and to your local board of health.** Providers in the city of Boston should report these cases directly to the Boston Public Health Commission at 617-534-5611. This applies to all strains of influenza:

- Suspected and confirmed deaths related to influenza in children under 18 and in pregnant women
- Unusual or unusually severe cases of influenza or ILI (e.g., with encephalopathy, myocarditis, or pericarditis)
- Case(s) or clusters of ILI in long-term care facilities, group homes, shelters, prisons or other high risk settings
- Unusual clusters of ILI in daycare and elementary schools
- Cases of suspected or proven antiviral treatment or prophylaxis failure
- Suspect novel or variant influenza, e.g., travel-associated, animal-associated, avian influenza A H5N1 or H7N9, influenza A H3N2v, or other highly pathologic avian influenza
- ILI in employees of swine or poultry farms

**Clusters in hospitals and long-term care:** Report clusters of influenza-like illness to MDPH via faxed teleform. Teleforms are available by calling 617-983-6801. Please provide as much detail on these forms as possible. Upon receipt of the teleform, an epidemiologist will contact you to provide guidance concerning testing, prophylaxis and infection control. Clusters in hospitals, long term care facilities and other entities licensed by the Division of Healthcare Quality (DHCQ) should also be reported to DHCQ at 800-462-5540 or 617-753-8150. Group homes, prisons or other settings should also contact the appropriate oversight agency for your facility.

2) **Report rapid influenza flu test results by teleform:** A teleform for reporting positive results of rapid influenza tests to MDPH is available by calling 617-983-6801.

3) **More about reporting:** For specific information about reporting, see the MDPH 105 CMR 300.000: Reportable Diseases, Surveillance and Isolation and Quarantine Requirements at [www.mass.gov/eohhs/docs/dph/cdc/reporting/rdiq-reg-summary.rtf](http://www.mass.gov/eohhs/docs/dph/cdc/reporting/rdiq-reg-summary.rtf). Please note that additional jurisdiction-specific reporting requirements may also apply. For example, healthcare providers and laboratories within the city of Boston must also report all cases of influenza and all laboratory tests positive for influenza directly to the Boston Public Health Commission (see [www.bphc.org/](http://www.bphc.org/) or contact BPHC at 617-534-5611).

**Influenza testing and infection control (including antiviral treatment), below:** Providers should routinely check for updates at [www.mass.gov/flu](http://www.mass.gov/flu) and [www.cdc.gov/flu/professionals/](http://www.cdc.gov/flu/professionals/).

**Influenza Testing:**
Diagnostic testing for influenza can aid clinical judgment and guide treatment decisions and control measures. Clinical testing services performed on specimens submitted to a state public health laboratory provide important diagnostic information to the clinician and also contribute to public health respiratory surveillance response and control measures. As a specific example, an influenza B strain submitted to the Massachusetts State Public Health Laboratory (MA SPHL) in March 2012 was the first identified isolate that later began to circulate widely and was then incorporated into the 2013-14 and 2014-15 influenza vaccines. Specific testing services provided by the MA SPHL may assist the clinician as follows:

- **Define the start of the influenza season:** Rapid antigen testing for detecting influenza A and B virus infections is widely available. Rapid influenza diagnostic tests vary in performance characteristics. False
negative and false positive results can occur when flu prevalence is low in the community. For this reason, MA SPHL requests that clinical laboratories consider submitting their first influenza rapid positive original samples of the season (beginning in October) to MA SPHL for confirmation. For more information: www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm.

- **Diagnose influenza or other respiratory infections:** Diagnostic tests for influenza performed at the MA SPHL include a "respiratory panel" to identify seasonal and novel influenza types/subtypes followed by testing of influenza negative samples for the presence of adenovirus, respiratory syncytial virus (A/B), parainfluenza virus (1-4), coronavirus (HKU1, OC43, NL63, 229E), human metapneumovirus and rhinovirus/enterovirus using polymerase chain reaction (PCR). There is no charge for these tests. The turnaround time for results is usually a few days, but varies depending on the test performed. Results are returned electronically or by fax and mail to the submitting provider.

- **Monitor trends in influenza antiviral resistance:** MA SPHL performs surveillance testing for influenza antiviral resistance and provides this information in its weekly influenza report. Diagnostic antiviral resistance testing is currently coordinated with CDC and is offered on a case-by-case basis. Providers are encouraged to submit samples from influenza cases with suspect antiviral drug resistance.

- **Rapid identification of new or novel influenza or other viral infections:** MA SPHL is able to rapidly determine the presence of a novel or variant influenza strain using the CDC diagnostic panel. Rapid antigen testing and commercially-available RT-PCR tests may not detect novel or variant strains of influenza and most are unable to differentiate between seasonal, novel or variant influenza strains. Therefore, respiratory specimens should be collected from any patient suspected of having atypical or novel infections with H3N2v or avian influenza H7N9, for example. These suspicions may be based on travel history or animal exposure.

**Specimen Collection and Shipping to MA SPHL:**
Flu specimens should be collected as soon as possible after onset of illness, preferably within three days (72 hours). Specimens collected after 72 hours are usually unsuitable for testing. Specimens should be submitted immediately after collection to MA SPHL in order to be tested within three days of collection. If samples will be shipped to MA SPHL ≥3 days from collection or on a Friday but are collected within 72 hrs, they should be frozen at <−20°C and shipped with ice packs on Monday. This variation must be noted on the specimen submission form to avoid an “unsatisfactory for testing” designation.

- For information on influenza specimen collection and transportation, or to speak with an immunization epidemiologist, call MDPH at 617-983-6800.

- Information of specimen collection and submission, including the respiratory surveillance specimen submission form may be found at: www.mass.gov/eohhs/docs/dph/laboratory-sciences/flu-virus-collection.pdf and www.mass.gov/eohhs/docs/dph/laboratory-sciences/flu-specimen-submission-form.pdf.

**Infection Control:** To prevent the transmission of all respiratory infections, including influenza, in health care settings, implement the following infection control measures at the first point of contact with a potentially infected person. These should be incorporated into infection control practices as one component of standard precautions. Tools to help promote and implement these recommendations are available at www.cdc.gov/flu/professionals/infectioncontrol.

1) **Assess the influenza and pneumococcal vaccination status of all patients** and the flu vaccination status of all staff. Vaccinate all susceptible patients and staff.


3) **Active surveillance and testing for new illness and cases:** Educate staff about the signs and symptoms of influenza-like illness.

4) **Respiratory hygiene/cough etiquette:** Post visual alerts (in appropriate languages) at the entrance to outpatient facilities (e.g., emergency departments, physician offices, outpatient clinics) instructing patients and persons who accompany them (e.g., family, friends) to inform health care personnel of symptoms of a respiratory infection when they first register for care and to practice respiratory hygiene/cough etiquette.
Posters, brochures and fact sheets promoting **cough etiquette** and **handwashing** in multiple languages are available from the Massachusetts Health Promotion Clearinghouse at [https://massclearinghouse.ehs.state.ma.us/](https://massclearinghouse.ehs.state.ma.us/).

5) **Novel strains of influenza:** If you suspect any novel strain of influenza, please contact your local board of health and MDPH immediately at 617-983-6800. Highly-pathogenic avian influenza (HPAI) A H5 viruses were identified in birds in the United States in December 2014 and the first half of 2015. The majority of these infections occurred in poultry, including backyard and commercial flocks. These HPAI A H5 viruses are not known to have caused disease in humans. There have been no cases identified in Massachusetts birds to date. Providers should check for updates at [http://www.cdc.gov/flu/avianflu/index.htm](http://www.cdc.gov/flu/avianflu/index.htm) and [http://www.cdc.gov/flu/swineflu/prevention-strategies.htm](http://www.cdc.gov/flu/swineflu/prevention-strategies.htm).

6) **Antiviral drugs** are an adjunct to, not a substitute for, vaccination for preventing and controlling influenza. The neuraminidase inhibitors oseltamivir (Tamiflu®), zanamivir (Relenza®), and peramivir (Rapivab®) are currently recommended for use against circulating influenza viruses. The adamantanes (amantadine and rimantadine) are not recommended because of high levels of resistance to these drugs among recently circulating influenza A (H3) and 2009 H1N1 influenza viruses.

**Prompt empiric antiviral treatment:** Clinical judgment is an important factor in treatment decisions for patients presenting with influenza-like illness. Prompt empiric antiviral treatment with influenza antiviral medications is recommended while results of definitive diagnostic tests are pending, or if diagnostic testing is not possible, for patients with clinically suspected influenza illness who have:

- Illness requiring hospitalization,
- Progressive, severe, or complicated illness, regardless of previous health status, and/or
- Increased risk for severe disease.

Antiviral treatment, when clinically indicated, should **not be delayed pending definitive laboratory confirmation of influenza**. Influenza antiviral medications are most effective when initiated within the first 2 days of illness, but these medications may also provide benefits for severely ill patients when initiated even after 2 days. Guidance on use of antivirals may change depending upon resistance data. Consult CDC’s latest recommendations on antiviral use at [www.cdc.gov/flu/professionals/antivirals/](http://www.cdc.gov/flu/professionals/antivirals/).

**Clinicians should be alert to changes in antiviral recommendations that might occur as additional antiviral resistance data becomes available during the 2016-2017 season.**

7) **Rapid testing reminder:** Point of care rapid tests capable of detecting influenza A and B virus infections are available, but health care providers and public health personnel should be aware that rapid influenza diagnostic tests have limited sensitivity and false negative results are common. Thus, negative results from rapid influenza diagnostic test should not be used to guide decisions regarding treating patients with influenza antiviral medications. In addition, false positive tests can occur and are more likely when influenza is rare in the community. When laboratory confirmation is desired, use RT-PCR and/or viral culture.

**Vaccine Ordering and Locating Clinics:**

**Providers Wishing to Order Flu Vaccine for Private Purchase:**
The national Influenza Vaccine Availability Tracking System (IVATS) assists providers wishing to privately purchase flu vaccine. IVATS identifies available doses of influenza vaccine by formulation and distributor/vendor throughout the season.

**Location of Flu and Adult Vaccination Services:**
Flu vaccination clinics are listed on the [mylocalclinic.com](http://mylocalclinic.com) website sponsored by the Massachusetts Health Officers Association (MHOA). MDPH urges agencies to post their clinics on this website. Many boards of health (BOHs) may have clinics that make flu and other vaccines available to both adults and children. BOHs can be contacted individually for questions about possible flu vaccination clinics in Massachusetts municipalities, including the age groups served.

**HealthMap Vaccine Finder** assists the public with locating influenza and adult vaccination services within their communities. It is a free, online service where users can search for locations that offer immunizations. Its staff works with partners such as clinics, pharmacies, and health departments to provide accurate and up-to-date information about vaccination services. MDPH urges providers and other agencies to register their locations on the HealthMap Vaccine Finder site too.
Guidance and Resources for Large Scale Immunization Clinics:

- **Guidelines for Large-Scale Influenza Vaccination Clinic Planning.** This webpage provides guidelines and recommendations to assist with planning influenza vaccination clinics. Topics include clinic logistics as well as vaccine storage, handling, and administration.

- **Checklist of Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off Site Locations.** Outlines CDC’s Best Practices that are essential for patient safety and vaccine effectiveness in these settings.

- **CDC At-A-Glance Resource Guide - Vaccine Administration and Storage and Handling.** This is a quick guide to key web resources on immunization, vaccine administration, and vaccine storage and handling. The guide includes CDC guidelines, an immunization checklist, educational webinars, and standing orders.

- **MDPH Influenza Vaccine Guidelines and Tools.** This webpage contains information about influenza vaccine and links to guidance about planning flu and other mass immunization campaigns, standing orders, screening forms, consent forms, and MDPH-specific vaccine management guidance.

- **One & Only Campaign.** The One & Only Campaign is a public health campaign, led by the Centers for Disease Control and Prevention (CDC) and the Safe Injection Practices Coalition (SIPC), to raise awareness among patients and healthcare providers about safe injection practices.
  - [Frequently Asked Questions](#) Regarding Safe Practices for Medical Injections
  - [Pocket Card](#) on Injection Safety Guidelines from CDC

**Pneumococcal Vaccine Recommendations**

Since 2014, the ACIP recommends that PCV13 and PPSV23 should be administered routinely in a series to all immunocompetent adults aged ≥65 years. **PCV13** should be administered only once for all adults. The recommended intervals between PCV13 and PPSV23 vaccines were updated last year and published in the MMWR.

Specific recommendations are based on a person’s previous pneumococcal vaccine history.

- **Persons who are pneumococcal vaccine-naïve.** Adults aged ≥65 years who have not previously received pneumococcal vaccine or whose previous vaccination history is unknown should receive a single dose of PCV13 first, followed by a dose of PPSV23. The dose of PPSV23 should be given ≥1 year after a dose of PCV13. If PPSV23 cannot be given during this time window, the dose of PPSV23 should be given during the next visit.

- **Persons previously vaccinated with PPSV23.** Adults aged ≥65 years who have previously received ≥1 doses of PPSV23 also should receive a single dose of PCV13 if they have not yet received it. A dose of PCV13 should be given ≥1 year after receipt of the most recent PPSV23 dose. For those for whom an additional dose of PPSV23 is indicated, this subsequent PPSV23 dose should be given ≥1 year after PCV13 and ≥5 years after the most recent dose of PPSV23.

- **Persons previously vaccinated with PPSV23.** Adults aged ≥65 years who have previously received ≥1 doses of PPSV23 also should receive a single dose of PCV13 if they have not yet received it. A dose of PCV13 should be given ≥1 year after receipt of the most recent PPSV23 dose. For those for whom an additional dose of PPSV23 is indicated, this subsequent PPSV23 dose should be given ≥1 year after PCV13 and ≥5 years after the most recent dose of PPSV23.

- The two vaccines should not be co-administered. If doses of PPSV23 and PCV13 are inadvertently given on the same day or earlier than the recommended interval, those doses do not need to be repeated.

- Adults 19 years and older at increased risk for pneumococcal disease who have already received a dose of PCV13 at 64 years or younger should **not** receive another dose of PCV13 at 65 years or older.

- For adults >65 years with immunocompromising conditions, functional or anatomic asplenia, CSF fluid leaks or cochlear implants, the recommended interval between a dose of PCV13 and PPSV23 remains at ≥8 weeks. This interval minimized the risk window for invasive pneumococcal disease caused by serotypes unique to PPSV23 in these highly vulnerable groups.

For more details about the sequential schedule and intervals, please see the algorithm below.

**Sequential Administration and Recommended Intervals for PCV13 and PPSV23 for Immunocompetent Adults Aged ≥65 Years**
1 If doses of PPSV23 and PCV13 are inadvertently given on the same day or earlier than the recommended interval, those doses do not need to be repeated.

2 For adults in this age group with immunocompromising conditions, functional or anatomic asplenia, CSF fluid leaks or cochlear implants, the recommended interval is ≥8 weeks.

3 For those who previously received PPSV23 when aged <65 years and for whom an additional dose of PPSV23 is indicated when aged ≥65 years, this subsequent PPSV23 dose should be given ≥1 year after PCV13 and ≥5 years after the most recent dose of PPSV23.

The above figure only outlines pneumococcal vaccine recommendations for those ≥65 years of age. The CDC job aid Pneumococcal Vaccine Timing for Adults contains a number of algorithms and a summary table. It was developed to help providers understand the complex pneumococcal recommendation across both age and risk groups -- and is an outstanding resource.

The recommendations for routine PCV13 use among adults aged ≥65 years will be reevaluated and revised as needed. CDC’s Pneumococcal Frequently Asked Questions was developed to help healthcare professionals address common questions patients ask regarding pneumococcal vaccination. Information and other resources can be found on CDC’s Pneumococcal Disease and Pneumococcal Vaccination web pages. MDPH’s Control of Influenza and Pneumococcal Disease in Long-Term Care Facilities contains additional guidance and will be posted at www.mass.gov/flu.

**Insurance Coverage and Pneumococcal Vaccines**

Most private health insurance covers pneumococcal vaccines. Check with the insurance provider for details on whether there is any cost to your patient and for a list of in-network vaccine providers. Medicare Part B covers the cost of two recommended doses of pneumococcal vaccine when administered 1 year apart. (i.e., 11 full months have passed following the month in which the previous pneumococcal vaccine was administered). As with other preventive care and vaccines, Medicare beneficiaries may not need to pay for the immunization if the doctor or other qualified health care provider accepts assignment (Medicare payment) for giving the vaccine. However, patients should check with their provider and plan to review the details of their coverage. Guidance for providers about Medicare Part B billing for pneumococcal vaccines can be found at: http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM9051.pdf

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Trade Name</th>
<th>Manufacturer</th>
<th>Presentation</th>
<th>Mercury Content from Thimerosal (μg Hg/0.5 mL)</th>
<th>Age Indication</th>
<th>Dose</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumococcal vaccine-naïve persons aged ≥65 years:</td>
<td>PCV13 at age ≥65 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Persons who previously received PPSV23 at age ≥65 years:</td>
<td>PPSV23 already received at age ≥65 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Persons who previously received PPSV23 before age 65 years who are now aged ≥65 years:</td>
<td>PPSV23 already received at age &lt;65 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Approved Inactivated Influenza Vaccines for Different Ages 2016-2017

1 If doses of PPSV23 and PCV13 are inadvertently given on the same day or earlier than the recommended interval, those doses do not need to be repeated.

2 For adults in this age group with immunocompromising conditions, functional or anatomic asplenia, CSF fluid leaks or cochlear implants, the recommended interval is ≥8 weeks.

3 For those who previously received PPSV23 when aged <65 years and for whom an additional dose of PPSV23 is indicated when aged ≥65 years, this subsequent PPSV23 dose should be given ≥1 year after PCV13 and ≥5 years after the most recent dose of PPSV23.
<table>
<thead>
<tr>
<th>IIV4 Standard Dose</th>
<th>Vaccine</th>
<th>Manufacturer</th>
<th>Dose (mL)</th>
<th>Adjuvant</th>
<th>Age Range</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluzone Quadrivalent</td>
<td>Sanofi Pasteur</td>
<td>0.25 mL PFS</td>
<td>0.0</td>
<td></td>
<td>6 - 35 mos</td>
<td>IM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5 mL PFS</td>
<td>0.0</td>
<td></td>
<td>≥ 3 years</td>
<td>IM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5 mL SDV</td>
<td>0.0</td>
<td></td>
<td>≥3 years</td>
<td>IM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5.0 mL MDV</td>
<td>25</td>
<td></td>
<td>6 - 35 mos</td>
<td>IM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≥3 yrs</td>
<td>IM</td>
</tr>
<tr>
<td>FluLaval Quadrivalent</td>
<td>ID Biomedical (distributed by GSK)</td>
<td>0.5 mL PFS</td>
<td>0.0</td>
<td></td>
<td>≥ 6 mos</td>
<td>IM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5.0 mL MDV</td>
<td>&lt; 25.0</td>
<td></td>
<td>(NEW, 12/16)</td>
<td>IM</td>
</tr>
<tr>
<td>Fluarix Quadrivalent</td>
<td>GSK</td>
<td>0.5 mL PFS</td>
<td>0.0</td>
<td></td>
<td>≥ 3 yrs</td>
<td>IM</td>
</tr>
<tr>
<td>Afluria Quadrivalent</td>
<td>Seqirus</td>
<td>0.5 mL PFS</td>
<td>0.0</td>
<td></td>
<td>≥18 yrs via needle</td>
<td>IM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluzone Intradermal</td>
<td>Sanofi Pasteur</td>
<td>0.1 mL prefilled microinjection</td>
<td>0.0</td>
<td></td>
<td>18-64 yrs</td>
<td>ID</td>
</tr>
<tr>
<td>IIV4 Cell Culture Based (ccIIV4) Standard Dose</td>
<td>Fluclenvax Quadrivalent</td>
<td>Seqirus</td>
<td>0.5 mL PFS</td>
<td>0.0</td>
<td>≥ 4 yrs</td>
<td>IM</td>
</tr>
<tr>
<td>IIV3 Standard Dose</td>
<td>Fluvirin</td>
<td>Seqirus</td>
<td>0.5 mL PFS</td>
<td>≤ 1</td>
<td>≥4 yrs</td>
<td>IM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5.0 mL MDV</td>
<td>25.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Afluria Trivalent</td>
<td>Seqirus</td>
<td>0.5 mL PFS</td>
<td>0.0</td>
<td></td>
<td>≥ 9 yrs via needle</td>
<td>IM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18-64 yrs via jet injector</td>
<td>IM</td>
</tr>
<tr>
<td>Adjuvanted Trivalent Standard Dose (aIIV3)</td>
<td>Fluad</td>
<td>Seqirus</td>
<td>0.5 mL PFS</td>
<td>0.0</td>
<td>≥65 yrs</td>
<td>IM</td>
</tr>
<tr>
<td>IIV3 High Dose</td>
<td>Fluzone High Dose</td>
<td>Sanofi Pasteur</td>
<td>0.5 mL PFS</td>
<td>0.0</td>
<td>≥ 65 yrs</td>
<td>IM</td>
</tr>
<tr>
<td>Recombinant Trivalent (RIV3)</td>
<td>Flublok (Does NOT contain any ovalbumin)</td>
<td>Protein Sciences</td>
<td>0.5 mL SDV</td>
<td>0.0</td>
<td>≥18 yrs</td>
<td>IM</td>
</tr>
</tbody>
</table>

**Abbreviations:**  IM= intramuscular; ID=intradermal; MDV = multi-dose vial; PFS = single-dose prefilled syringe; SDV = single-dose vial

(See footnotes next page.)
Footnotes:
1 Check Food and Drug Administration for approved prescribing information for 2016-17 influenza vaccines for the most updated information, including (but not limited to) indications, contraindications, and precautions. Package inserts are available at http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm

2 The column for ovalbumin concentration has been removed. Although history of severe allergic reaction to egg is a labeled contraindication to IIV and LAIV, the ACIP currently recommends that ANY licensed IIV or RIV may be administered to persons with egg allergy of any sensitivity.

However, persons with a history of severe egg allergy (i.e., any symptom other than hives) should be vaccinated any licensed, recommended and age-appropriate influenza formulation in an inpatient or outpatient medical setting (including but not necessarily limited to hospitals, clinics, schools, health departments, and physician offices), under the supervision of a health care provider who is able to recognize and manage severe allergic reactions.

Please note: Flublok does NOT contain any egg protein (see footnote 8) and Flucelvax contains <50 femtograms (see footnote 4).

3 On 11-18-16, the FDA lowered the minimum age for use of FluLaval from 3 years old to 6 months old. FluLaval is approved as a 0.5 mL dose for all approved age groups, including in this younger age group. New 12/16

4 Quadrivalent inactivated vaccine, intradermal: A 0.1-mL dose contains 9 μg of each vaccine antigen (36 μg total).

5 For Flucelvax this information is not included in the package insert. This cell culture vaccine has a much smaller amount of egg protein since the original virus was grown in eggs, but mass production of that vaccine does not occur in eggs. Flucelvax contains an estimated total egg protein that is less than 50 femtograms (5x10^-8g) total egg protein (and less ovalbumin) per 0.5 mL dose. (Personal communication Seqirus 8-2-16)

6 Age indication per package insert is ≥ 5 years; however, the ACIP recommends Afluria Trivalent not be used in children aged 6 months through 8 years because of increased risk of febrile reactions noted in this age group with bioCSL’s 2010 Southern Hemisphere IIV3 formulation. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5 - 8 years who has a medical condition that increases the child's risk for influenza complications, Afluria Trivalent can be used. Discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria Trivalent before administering this vaccine. Afluria Trivalent may be used in persons ≥9 years.

7 Trivalent inactivated vaccine, high-dose: A 0.5-mL dose contains 60 μg of each vaccine antigen (180 μg total).

8 Fluad is standard dose of IIV3 and contains MF-59 as an adjuvant.

9 Flublok is a recombinant vaccine that does NOT contain ANY ovalbumin.

Package inserts for all flu vaccine formulations: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm

Resources and Questions:
For complete guidance, see ACIP’s 2016-2017 Recommendations for Prevention and Control of Influenza with Vaccines at http://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6505.pdf. CDC will be updating its flu website to reflect the new recommendations, including those about LAIV for both providers and patients. So please check their website: www.cdc.gov/flu. The MDPH Flu website at www.mass.gov/flu has information for providers and the general public. Click on 'Information for Healthcare Professionals' for provider resources such as clinical advisories and control guidance, model standing orders, screening forms and planning clinics and campaigns.

For questions about influenza please call the Massachusetts Department of Public Health Immunization Program at 617-983-6800 or your local board of health. For questions about state-supplied influenza vaccine, please call the Vaccine Unit at 617-983-6828.

References:


CDC. Injection Safety and Vaccine Administration Errors at an Employee Influenza Vaccination Clinic, New Jersey, 2015. MMWR 2016:1363-1364.
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6449a3.htm


Vaccine Information Statements (VISs) for all vaccines in many languages: www.immunize.org/vis.

Standing orders for LAIV, IIV, pneumococcal vaccine, Tdap and other vaccines are available at www.immunize.org or www.mass.gov/dph/imm

Visit the MDPH web site (www.mass.gov/flu). Hard copies and technical consultation are available by calling MDPH at 617-983-6800 or 888-658-2850.